The renin-angiotensin-aldosterone system (RAAS) is the dominant hormonal regulator of systemic blood pressure, sodium-water balance, and vascular tone. Its enzymatic cascade converts an inactive plasma protein into one of the most potent vasoconstrictor peptides known, and pharmacological interruption of this cascade at multiple points constitutes the foundation of modern cardiovascular therapeutics. A precise understanding of each step in the cascade is prerequisite to understanding the mechanisms and adverse effect profiles of the drugs that target it.
Renin is an aspartyl protease synthesized and stored as prorenin in the juxtaglomerular (JG) cells of the afferent arteriole in the kidney. Three primary stimuli trigger renin secretion from JG cells: reduced renal perfusion pressure sensed by the afferent arteriolar baroreceptor, reduced sodium chloride delivery to the macula densa of the distal tubule, and sympathetic nervous system activation via beta-1 adrenergic receptors on JG cells. Once released into the systemic circulation, renin cleaves angiotensinogen, an alpha-2-globulin produced constitutively by the liver, at a specific leucine-valine bond to yield the decapeptide angiotensin I (Ang I). Angiotensin I is pharmacologically inert; it circulates as the immediate substrate for the next enzymatic step and has no significant direct receptor activity at physiological concentrations.1
Angiotensin-converting enzyme (ACE), also designated kininase II, is a membrane-bound zinc metallopeptidase expressed at high density on the luminal surface of pulmonary vascular endothelium and, to a lesser extent, on vascular endothelium throughout the systemic circulation. ACE cleaves two amino acids from the carboxy-terminus of angiotensin I to generate the octapeptide angiotensin II (Ang II), a reaction that occurs with near-complete efficiency during a single pass through the pulmonary circulation. Because ACE is a dipeptidyl carboxypeptidase, it also hydrolyzes bradykinin at the same active site, inactivating bradykinin. This dual substrate specificity is the mechanistic explanation for why ACE inhibitors simultaneously increase bradykinin levels and reduce angiotensin II levels, a pharmacological consequence with major clinical implications for both therapeutic effects and adverse effects.2
Angiotensin II exerts its principal cardiovascular actions through two receptor subtypes. The AT1 receptor, a Gq-coupled seven-transmembrane receptor expressed on vascular smooth muscle, adrenal cortex, kidney, heart, and brain, mediates virtually all of the classical RAAS effects: vasoconstriction via phospholipase C activation and intracellular calcium mobilization; aldosterone secretion from the zona glomerulosa; renal sodium and water retention; sympathetic nervous system facilitation; and cardiac and vascular hypertrophy through growth-promoting signaling pathways including the mitogen-activated protein kinase (MAPK) cascade. The AT2 receptor, expressed at lower density in adults but upregulated in pathological states such as heart failure and after myocardial infarction (MI), signals through Gi-coupled pathways and generally opposes AT1-mediated effects, promoting vasodilation, natriuresis, anti-proliferation, and apoptosis. The net physiological effect of angiotensin II at normal circulating concentrations is dominated by AT1 receptor signaling.1
Aldosterone, the mineralocorticoid secreted from the adrenal zona glomerulosa in response to angiotensin II and also to hyperkalemia and adrenocorticotropic hormone (ACTH), acts on the mineralocorticoid receptor (MR) in the renal collecting duct principal cells to increase expression of epithelial sodium channels (ENaC) on the luminal membrane and Na+/K+-ATPase on the basolateral membrane, driving sodium reabsorption and potassium excretion. In pathological states including heart failure and chronic kidney disease (CKD), aldosterone escape from RAAS suppression is a clinically important phenomenon: after initial renin-angiotensin system blockade reduces Ang II and aldosterone, aldosterone levels may return toward baseline over weeks to months through angiotensin-independent stimulation by potassium and ACTH. This escape is a rationale for adding mineralocorticoid receptor antagonists (MRAs) to ACE inhibitor or angiotensin receptor blocker (ARB) therapy in heart failure with reduced ejection fraction (HFrEF), as demonstrated in the RALES and EPHESUS trials.3
In HFrEF, reduced cardiac output activates the RAAS through two mechanisms: reduced renal perfusion pressure stimulates JG cell renin secretion, and sympathetic activation directly stimulates beta-1 adrenergic receptors on JG cells. The resulting angiotensin II and aldosterone elevation produces vasoconstriction, sodium retention, and cardiac remodeling that initially compensate for reduced output but over time accelerate ventricular dysfunction. This is the pathophysiological basis for the mortality benefit of ACEi and ARBs in heart failure. In bilateral renal artery stenosis (RAS, renal artery stenosis), both kidneys are ischemic and renin secretion is maximally stimulated; Ang II-mediated efferent arteriolar constriction is the primary mechanism maintaining glomerular filtration rate (GFR) in this setting. Initiating an ACEi or ARB removes this Ang II-dependent support of GFR and precipitates acute kidney injury (AKI) – the mechanistic basis for the contraindication of RAAS-blocking agents in bilateral RAS.
ACE inhibitors block the zinc metallopeptidase active site of ACE with high affinity, reducing angiotensin II generation and simultaneously preventing bradykinin degradation. These two consequences are pharmacologically inseparable because they share a single enzymatic mechanism, and both contribute to the clinical profile of the class. The bradykinin accumulation that mediates ACEi cough and angioedema is not a drug-specific idiosyncrasy but a class-wide pharmacodynamic consequence of ACE inhibition, present to some degree in all patients on ACEi therapy.
The zinc metallopeptidase active site of ACE contains a zinc ion coordinated by histidine residues within a hydrophobic binding pocket. ACE inhibitors present a zinc-coordinating ligand (sulfhydryl in captopril, carboxylate in enalaprilat and most others, phosphonate in fosinoprilat) that binds to the zinc ion with high affinity, competitively and reversibly occupying the active site and preventing substrate access. The reduction in angiotensin II generation at AT1 (angiotensin type 1) receptors produces the therapeutic cardiovascular and renal effects. The concurrent reduction in bradykinin degradation is quantitatively important because ACE (kininase II) is one of the two principal enzymes responsible for bradykinin inactivation, alongside carboxypeptidase N. When ACE is inhibited, bradykinin half-life in tissues and plasma is extended, and local bradykinin concentrations at vascular endothelial surfaces increase. This bradykinin accumulation activates endothelial B2 receptors, increasing nitric oxide (NO) and prostacyclin (PGI2) generation, which contribute to the vasodilatory and potentially cardioprotective effects of the class beyond what can be attributed to Ang II reduction alone.2
ACEi-induced cough occurs in 5–20% of patients on ACE inhibitor therapy, with higher incidence in East Asian populations (up to 30–40%) compared to populations of European ancestry (5–10%). The mechanism involves bradykinin accumulation in the pulmonary interstitium, where bradykinin stimulates B2 receptors on airway sensory C-fibers. B2 receptor activation in this context increases arachidonic acid release via phospholipase A2, generating prostaglandin E2 (PGE2) and thromboxane A2 locally; these eicosanoids sensitize the cough reflex arc at the level of bronchial afferent fibers, lowering the threshold for cough in response to inhaled irritants. The cough is characteristically dry and non-productive, often described as a tickle or irritation in the throat, and it does not respond to antihistamines, beta-agonists, or antitussives. Switching to an ARB (angiotensin receptor blocker), which does not affect bradykinin metabolism, resolves the cough in virtually all cases. The genetic variability in cough incidence between populations reflects polymorphisms in bradykinin receptor genes, ACE gene expression levels, and prostaglandin synthesis pathway enzymes.4
ACEi-induced angioedema is a bradykinin-mediated phenomenon mechanistically distinct from IgE-mediated allergic angioedema, and this distinction has critical treatment implications. The overall incidence is 0.1–0.7% of treated patients, but Black patients of African ancestry have a 3–4-fold higher risk, a disparity attributed to lower baseline ACE activity, greater sensitivity of the bradykinin pathway, and genetic differences in bradykinin receptor expression. ACEi angioedema characteristically involves the tongue, lips, periorbital region, and larynx; laryngeal involvement occurs in 25–30% of cases and can be life-threatening. The edema is non-pitting, non-pruritic, and not accompanied by urticaria, distinguishing it from histamine-mediated allergic angioedema. The onset is typically within the first weeks of therapy, but paradoxically, angioedema can occur after years of uneventful ACEi use when bradykinin pathway sensitivity increases due to concurrent illness, estrogen exposure, or other factors that alter bradykinin generation or receptor sensitivity.4
ACEi-induced angioedema is driven by bradykinin acting on B2 receptors on vascular endothelium, not by histamine acting on H1 receptors on mast cells. Antihistamines block H1 receptors and are therefore ineffective. Epinephrine has no mechanism for reversing bradykinin-driven vascular permeability and should not be relied upon as definitive treatment, though it may provide transient benefit in laryngeal edema through vasoconstriction. Corticosteroids, which reduce IgE-mediated inflammation, are similarly ineffective. Immediate ACEi discontinuation is the primary intervention. For severe laryngeal angioedema, icatibant (a competitive B2 receptor antagonist, 30 mg subcutaneously) may hasten resolution; fresh frozen plasma (FFP), which contains functional ACE and carboxypeptidase N capable of degrading accumulated bradykinin, is a reasonable second-line option when icatibant is unavailable. See Chapter 21 (HistBrad-04) for full bradykinin treatment pharmacology.
Most ACE inhibitors in clinical use are orally administered prodrugs that require hepatic hydrolysis to release the active diacid form capable of binding the ACE active site with high affinity. This prodrug strategy was adopted to improve oral bioavailability, since the active diacid forms are poorly absorbed as such. Understanding the prodrug concept, the enzymes responsible for activation, and the renal elimination that is near-universal across the class is essential for appropriate dosing in patients with renal impairment, a population in whom ACEi are both most beneficial and most potentially harmful.
Captopril is the only ACE inhibitor that is both orally active and pharmacologically active as administered, without requiring biotransformation. It contains a sulfhydryl (-SH) group as its zinc-coordinating moiety. Its oral bioavailability is approximately 65–75% when administered fasting but decreases significantly when taken with food, making consistent fasting administration important for predictable plasma levels. The plasma half-life of captopril is approximately 2 hours, necessitating three-times-daily dosing for sustained ACE inhibition, a practical disadvantage compared to once-daily agents. Captopril undergoes partial hepatic metabolism and approximately 40–50% renal elimination of unchanged drug, requiring dose reduction in patients with creatinine clearance (CrCl) below 30 mL/min.5
Enalapril is the archetype ester prodrug ACE inhibitor. After oral absorption (bioavailability approximately 60%, unaffected by food), enalapril undergoes hepatic esterase-mediated hydrolysis to enalaprilat, the pharmacologically active diacid. Enalaprilat has a plasma half-life of approximately 11 hours (biphasic: initial 2-hour phase followed by a prolonged terminal phase reflecting tight tissue ACE binding), supporting twice-daily to once-daily dosing. Enalaprilat is eliminated almost entirely by the kidney; dose reduction is required when CrCl falls below 30 mL/min, and enalaprilat is dialyzable, meaning patients on hemodialysis may require supplemental dosing after each session. Lisinopril is distinct in being a lysine analog of enalaprilat that is itself orally active (no prodrug conversion required), with oral bioavailability of approximately 25% unaffected by food. Lisinopril is eliminated entirely by renal excretion of unchanged drug with a half-life of approximately 12 hours; significant accumulation occurs in CKD (chronic kidney disease), and dose reduction is required when CrCl is below 30 mL/min.5
Ramipril, perindopril, and fosinopril illustrate pharmacokinetic diversity within the class. Ramipril is hydrolyzed by hepatic esterases to ramiprilat, which has the highest ACE affinity of the class diacids and a functional half-life that supports once-daily dosing; ramiprilat undergoes predominantly renal elimination with a minor glucuronide conjugate pathway. Perindopril is hydrolyzed to perindoprilat, with approximately 75% of the active metabolite renally eliminated and the remainder in feces. Fosinopril is unique within the class in having a phosphonate zinc-coordinating group and dual hepatic/renal elimination of its active form fosinoprilat (approximately 50% renal, 50% biliary/fecal); this balanced elimination means fosinoprilat does not accumulate disproportionately in renal impairment, and dose adjustment is not required until CrCl falls below 10 mL/min, making fosinopril the preferred ACEi in advanced CKD.5
All ACE inhibitors except fosinopril require dose reduction in significant renal impairment (CrCl below 30 mL/min) because their active forms accumulate as GFR (glomerular filtration rate) declines. Start at 25–50% of the standard dose in patients with CrCl 10–30 mL/min and titrate to response. Fosinopril does not require adjustment until CrCl is below 10 mL/min. An initial rise in serum creatinine of up to 30% after ACEi initiation is expected in CKD; it reflects reduced glomerular hyperfiltration from efferent arteriolar dilation and is not a reason to discontinue therapy. A rise exceeding 30% or occurring rapidly suggests hemodynamic renal impairment from either bilateral RAS (renal artery stenosis) or severe volume depletion. Serum potassium must be monitored at baseline and 1–2 weeks after initiation or dose increase in all patients with CKD.
ACE inhibitors have among the broadest evidence bases of any drug class in cardiovascular medicine, with mortality benefits demonstrated in heart failure, post-myocardial infarction, high cardiovascular risk patients, and diabetic nephropathy. Their contraindications are mechanistically derived and strictly enforced, making an understanding of the underlying pharmacology essential for safe prescribing in the populations where they are simultaneously most beneficial and most potentially dangerous.
The primary cardiovascular indications for ACEi are well-established by landmark randomized trials. In HFrEF (heart failure with reduced ejection fraction), the CONSENSUS and SOLVD trials demonstrated significant mortality reduction with enalapril, establishing ACEi as foundational therapy. In the post-MI (myocardial infarction) setting, ACEi initiated within the first 24–36 hours and continued long-term reduce all-cause mortality, sudden cardiac death, and reinfarction rates, with the greatest benefit in patients with reduced ejection fraction or anterior MI location, as shown by the SAVE (captopril), AIRE (ramipril), and TRACE (trandolapril) trials.3 In high-cardiovascular-risk patients without heart failure, the HOPE trial demonstrated that ramipril reduced the composite of MI, stroke, and cardiovascular death by 22% versus placebo, a benefit attributable in part to bradykinin-mediated vascular protective effects beyond blood pressure reduction.6 In diabetic nephropathy, the Lewis trial established that captopril reduces proteinuria and delays progression to end-stage renal disease (ESRD) in type 1 diabetes with macroproteinuria, and subsequent evidence supports renoprotective effects in type 2 diabetes via reduction of intraglomerular hypertension through efferent arteriolar dilation.7
Hypertension is the broadest indication for ACEi, with all members of the class effective as antihypertensive monotherapy in the majority of patients, particularly those with high renin activity. ACEi are less effective as monotherapy in low-renin hypertension, which is more prevalent in older patients and Black patients of African ancestry; in these populations, thiazide diuretics or calcium channel blockers are preferred as initial therapy. The ALLHAT trial demonstrated that for prevention of cardiovascular events in high-risk hypertensive patients, chlorthalidone was at least as effective as lisinopril for primary outcomes, though the lisinopril arm had higher rates of stroke in Black patients, attributed to less effective blood pressure lowering at the doses used rather than to mechanism-specific inferiority.8
The absolute contraindications to ACEi therapy are bilateral renal artery stenosis (or unilateral RAS [renal artery stenosis] in a solitary functioning kidney), prior ACEi-induced angioedema, pregnancy, and concurrent use with sacubitril-valsartan. In bilateral RAS, Ang II-mediated efferent arteriolar constriction is the primary mechanism sustaining GFR (glomerular filtration rate) against the reduced perfusion pressure; ACEi removal of this efferent arteriolar tone causes acute, often severe kidney injury. In the post-MI and heart failure settings, where concurrent low systemic pressure and reduced renal perfusion can produce the same physiology even without anatomic RAS, extreme caution with close renal monitoring is required at ACEi initiation.3 In pregnancy, ACEi and ARBs (angiotensin receptor blockers) are absolutely contraindicated throughout all three trimesters. First-trimester exposure is associated with increased risk of cardiovascular and central nervous system malformations in infants.9 Second and third trimester exposure causes fetal renal tubular dysgenesis through suppression of fetal RAAS (renin-angiotensin-aldosterone system)-dependent renal development, leading to oligohydramnios, fetal anuria, limb contractures, pulmonary hypoplasia, and neonatal death in severe cases; this fetal toxicity is a class effect shared by ARBs.9
Mechanism: ACEi suppress aldosterone, reducing renal potassium excretion in the collecting duct. In patients with CKD (chronic kidney disease), reduced ability to excrete potassium via other tubular mechanisms amplifies this effect.
High-risk combinations: ACEi + potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene); ACEi + potassium supplements; ACEi + trimethoprim (blocks renal potassium secretion by the same tubular channel as amiloride); ACEi + NSAIDs (non-steroidal anti-inflammatory drugs; reduce aldosterone via prostaglandin inhibition, compounding the ACEi effect).
Monitoring: Serum potassium and creatinine at baseline, 1–2 weeks after initiation or dose change, and periodically thereafter. Hold ACEi if serum potassium exceeds 5.5 mEq/L; discontinue if above 6.0 mEq/L pending reassessment.
Dietary counseling: Patients at high risk (CKD stage 3b–5, concurrent MRA use) require dietary potassium restriction and avoidance of salt substitutes containing potassium chloride.
Aliskiren is the only clinically available direct renin inhibitor (DRI), targeting the cascade at its first and rate-limiting enzymatic step rather than at ACE. Despite its mechanistic logic, the clinical evidence from large outcomes trials has constrained its use to monotherapy in specific populations, and its combination with ACEi or ARBs (angiotensin receptor blockers) is now explicitly contraindicated in patients with diabetes or renal impairment. The ACEi drug interaction landscape is broad, with NSAIDs, potassium-sparing diuretics, and lithium representing the interactions most frequently encountered and most clinically consequential in practice.
Aliskiren binds directly to the active site of renin, competitively inhibiting its ability to cleave angiotensinogen to angiotensin I, thereby reducing the generation of all downstream RAAS components simultaneously. Unlike ACEi and ARBs, aliskiren reduces plasma renin activity (PRA) rather than causing the compensatory rise in PRA that occurs when ACE or AT1 (angiotensin type 1) receptors are blocked (since Ang II normally exerts negative feedback on renin secretion). The oral bioavailability of aliskiren is approximately 2.6%, attributable to poor gastrointestinal absorption and P-glycoprotein (P-gp)-mediated efflux back into the intestinal lumen. Aliskiren is a substrate for both cytochrome P450 3A4 (CYP3A4, minor metabolic pathway) and P-gp, but does not inhibit either, meaning it does not significantly alter the plasma concentrations of co-administered CYP3A4 or P-gp substrates. Its plasma half-life is approximately 24 hours, supporting once-daily dosing. Aliskiren is predominantly eliminated as unchanged drug via the hepatobiliary route, with only approximately 1–2% recovered in urine; this makes it one of the few renally-acting antihypertensive drugs that does not accumulate in renal impairment, though the pharmacodynamic concern about hyperkalemia and AKI applies equally to all RAAS-active agents.10
The combination of aliskiren with ACEi or ARBs was investigated in the ALTITUDE trial (aliskiren added to ACEi or ARB in patients with type 2 diabetes and CKD (chronic kidney disease) or cardiovascular disease) and the ONTARGET trial (telmisartan added to ramipril). Both trials demonstrated that dual RAAS blockade increased rates of AKI, hyperkalemia, and hypotension without reducing cardiovascular mortality or progressive kidney disease, compared to monotherapy. ONTARGET additionally showed that combination therapy increased the rate of dialysis requirement. Based on these data, regulatory agencies issued contraindications against the combination of aliskiren with ACEi or ARBs in patients with diabetes, and a strong warning against the combination in CKD. Dual ACEi-ARB therapy is similarly contraindicated for the same reasons, a point discussed further in PEP-02 in the context of sacubitril-valsartan prescribing.11
NSAIDs represent one of the most common and clinically consequential drug interactions with ACEi. The mechanism operates through NSAID inhibition of cyclooxygenase (COX) enzymes in the renal afferent arteriole and macula densa, reducing prostaglandin E2 (PGE2) and prostacyclin (PGI2) synthesis. These prostaglandins normally maintain afferent arteriolar dilation and support renal perfusion, particularly in states of reduced effective arterial volume such as heart failure, volume depletion, cirrhosis, or CKD. In the simultaneous presence of ACEi, which reduces Ang II-mediated efferent arteriolar constriction, the combination of reduced afferent dilation (NSAID effect) and reduced efferent constriction (ACEi effect) can dramatically reduce the intraglomerular pressure gradient and precipitate hemodynamic AKI. This interaction is particularly dangerous in elderly patients with CKD, congestive heart failure, or volume depletion on diuretics. The interaction extends equally to COX-2-selective inhibitors (celecoxib), which reduce renal PGE2 through the same mechanism and carry identical renal risk despite reduced gastrointestinal toxicity compared to non-selective NSAIDs.12
Lithium toxicity is a pharmacokinetic interaction with ACEi that warrants explicit clinical attention. ACEi-induced reduction in aldosterone decreases sodium reabsorption in the distal nephron; as a compensatory response, proximal tubular sodium reabsorption increases, and because lithium is handled by the proximal tubule similarly to sodium, proximal lithium reabsorption also increases, raising serum lithium concentrations toward toxic levels. This interaction is potentiated when ACEi are combined with diuretics, which further increase proximal sodium (and lithium) reabsorption through volume contraction. Lithium toxicity manifests as tremor, confusion, polyuria, and at severe levels cardiac arrhythmias and seizures. Serum lithium monitoring is mandatory within 1–2 weeks of initiating or dose-adjusting an ACEi in any patient receiving lithium, and lithium dose reduction will typically be required.12
ACEi + NSAIDs or COX-2 inhibitors: hemodynamic AKI risk, particularly in elderly patients with heart failure, CKD, or diuretic use; avoid when possible or monitor renal function closely. ACEi + potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene): hyperkalemia risk is additive; used intentionally in HFrEF but requires potassium monitoring every 1–4 weeks during initiation and dose titration. ACEi + trimethoprim: blocks the same collecting duct potassium secretion channel as amiloride; hyperkalemia risk in CKD. ACEi + lithium: lithium toxicity via increased proximal tubular reabsorption; monitor lithium levels within 1–2 weeks of any ACEi change. ACEi + aliskiren in diabetes or CKD: contraindicated (ALTITUDE data). ACEi + sacubitril-valsartan: contraindicated (angioedema risk; 36-hour washout required in both switching directions).
Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24(3):261–271.
doi:10.1210/er.2003-0001Skidgel RA, Erdos EG. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies. Peptides. 2004;25(3):521–525.
doi:10.1016/j.peptides.2003.12.010Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2013;62(16):e147–e239.
doi:10.1016/j.jacc.2013.05.019Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE inhibitor-induced angioedema: a review. Curr Hypertens Rep. 2018;20(7):55.
doi:10.1007/s11906-018-0859-xShionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet. 1993;25(1):20–58.
doi:10.2165/00003088-199325010-00003Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153.
doi:10.1056/NEJM200001203420301Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456–1462.
doi:10.1056/NEJM199311113292004ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981–2997.
doi:10.1001/jama.288.23.2981Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443–2451.
doi:10.1056/NEJMoa055202Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008;48(11):1323–1338.
doi:10.1177/0091270008323258Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–2213.
doi:10.1056/NEJMoa1208799Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy. Circulation. 2001;104(16):1985–1991.
doi:10.1161/hc4101.096153